141 related articles for article (PubMed ID: 35348408)
21. One time a day mometasone/indacaterol fixed-dose combination versus two times a day fluticasone/salmeterol in patients with inadequately controlled asthma: pooled analysis from PALLADIUM and IRIDIUM studies.
Chapman K; van Zyl-Smit R; Maspero J; Kerstjens HAM; Gon Y; Hosoe M; Tanase AM; Pethe A; Shu X; D'Andrea P
BMJ Open Respir Res; 2021 Aug; 8(1):. PubMed ID: 34452934
[TBL] [Abstract][Full Text] [Related]
22. Mometasone/Indacaterol/Glycopyrronium (MF/IND/GLY) and MF/IND at Different MF Strengths versus Fluticasone Propionate/Salmeterol Xinafoate (FLU/SAL) and FLU/SAL+ Tiotropium in Patients with Asthma.
van Zyl-Smit RN; Chapman KR; Kerstjens HAM; Gessner C; Sagara H; Tanase AM; Hosoe M; Pethe A; Lawrence D; Tillmann HC; D'Andrea P
J Asthma Allergy; 2023; 16():123-134. PubMed ID: 36714049
[TBL] [Abstract][Full Text] [Related]
23. Efficacy and safety of QVA149 compared to the concurrent administration of its monocomponents indacaterol and glycopyrronium: the BEACON study.
Dahl R; Jadayel D; Alagappan VK; Chen H; Banerji D
Int J Chron Obstruct Pulmon Dis; 2013; 8():501-8. PubMed ID: 24159259
[TBL] [Abstract][Full Text] [Related]
24. Once-daily, single-inhaler indacaterol/mometasone versus twice-daily salmeterol/fluticasone in Asian patients with inadequately controlled asthma:
Gon Y; Ishii T; Lawrence D; Nikolaev I; Wang D; Sumi K; Nakamura Y
J Asthma; 2022 Aug; 59(8):1627-1637. PubMed ID: 34346266
[TBL] [Abstract][Full Text] [Related]
25. Real-life effectiveness of indacaterol/glycopyrronium/mometasone for symptomatic relief of cough after switching from inhaled corticosteroid/long-acting β
Niimi A; Kanemitsu Y; Tajiri T; Sumi K; Mikami T; Kondo N
ERJ Open Res; 2023 Mar; 9(2):. PubMed ID: 37009022
[TBL] [Abstract][Full Text] [Related]
26. Cost-Effectiveness of Once-Daily, Single-Inhaler Indacaterol Acetate/ Glycopyrronium Bromide/ Mometasone Furoate in Patients with Uncontrolled Moderate-to-Severe Asthma in Canada.
Mtibaa M; Gupta S; Muthukumar M; Marvel J; Kaur H; Ishikawa R; Olivenstein R
Clinicoecon Outcomes Res; 2021; 13():957-967. PubMed ID: 34887668
[TBL] [Abstract][Full Text] [Related]
27. A randomized, double-blind study to compare the efficacy and safety of two doses of mometasone furoate delivered via Breezhaler® or Twisthaler® in patients with asthma.
Buhl R; Tanase AM; Hosoe M; Cao W; Demin I; Bartels C; Jauernig J; Ziegler D; Patalano F; Hederer B; Kanniess F; Tillmann HC
Pulm Pharmacol Ther; 2020 Jun; 62():101919. PubMed ID: 32387408
[TBL] [Abstract][Full Text] [Related]
28. Population Pharmacokinetic Analysis of Indacaterol/Glycopyrronium/Mometasone Furoate After Administration of Combination Therapies Using the Breezhaler
Bartels C; Jain M; Yu J; Tillmann HC; Vaidya S
Eur J Drug Metab Pharmacokinet; 2021 Jul; 46(4):487-504. PubMed ID: 34024035
[TBL] [Abstract][Full Text] [Related]
29. Long-term safety of mometasone furoate/formoterol combination for treatment of patients with persistent asthma.
Maspero JF; Nolte H; Chérrez-Ojeda I;
J Asthma; 2010 Dec; 47(10):1106-15. PubMed ID: 20874458
[TBL] [Abstract][Full Text] [Related]
30. Triple Therapy with Mometasone/Indacaterol/Glycopyrronium or Doubling the ICS/LABA Dose in GINA Step 4: IRIDIUM Analyses.
van Zyl-Smit RN; Kerstjens HAM; Maspero J; Tanase AM; Lawrence D; Mezzi K; D'Andrea P; Chapman KR
Pulm Ther; 2023 Sep; 9(3):395-409. PubMed ID: 37526856
[TBL] [Abstract][Full Text] [Related]
31. Efficacy of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Versus Other Inhaled Corticosteroid/Long-Acting Muscarinic Antagonist/Long-Acting β
Ferguson GT; Darken P; Ballal S; Siddiqui MK; Singh B; Attri S; Holmgren U; de Nigris E
Adv Ther; 2020 Jun; 37(6):2956-2975. PubMed ID: 32335859
[TBL] [Abstract][Full Text] [Related]
32. Efficacy of mometasone/indacaterol/glycopyrronium in patients with inadequately controlled asthma with respect to baseline eosinophil count: Post hoc analysis of IRIDIUM study.
Kostikas K; Maspero JF; Chapman KR; Mezzi K; Jaumont X; Lawrence D; van Zyl-Smit R
Respir Med; 2023 Oct; 217():107334. PubMed ID: 37392789
[TBL] [Abstract][Full Text] [Related]
33. Indacaterol, glycopyrronium, and mometasone: Pharmacological interaction and anti-inflammatory profile in hyperresponsive airways.
Rogliani P; Ritondo BL; Facciolo F; Matera MG; Nikolaev I; Calzetta L
Pharmacol Res; 2021 Oct; 172():105801. PubMed ID: 34363950
[TBL] [Abstract][Full Text] [Related]
34. Serious Asthma Outcomes and Asthma Exacerbations with Maintenance on Inhaled Corticosteroid (Mometasone Furoate)/Long-Acting Beta Agonist (Formoterol) Combination Compared to Step Down to Mometasone Monotherapy.
Weinstein CLJ; Ryan N; Zhang X; Shekar T; Gates D; Lane SJ; Agache I; Nathan RA;
J Allergy Clin Immunol Pract; 2020 May; 8(5):1634-1644.e1. PubMed ID: 31981733
[TBL] [Abstract][Full Text] [Related]
35. Effect of once-daily indacaterol maleate/mometasone furoate on exacerbation risk in adolescent and adult asthma: a double-blind randomised controlled trial.
Beasley RW; Donohue JF; Mehta R; Nelson HS; Clay M; Moton A; Kim HJ; Hederer BM
BMJ Open; 2015 Feb; 5(2):e006131. PubMed ID: 25649209
[TBL] [Abstract][Full Text] [Related]
36. Real-life effectiveness of indacaterol-glycopyrronium after switching from tiotropium or salmeterol/fluticasone therapy in patients with symptomatic COPD: the POWER study.
Kaplan A; Chapman KR; Anees SM; Mayers I; Rochdi D; Djandji M; Préfontaine D; McIvor A
Int J Chron Obstruct Pulmon Dis; 2019; 14():249-260. PubMed ID: 30718952
[TBL] [Abstract][Full Text] [Related]
37. Efficacy and Safety of Indacaterol/Glycopyrronium (IND/GLY) Versus Salmeterol/Fluticasone in Chinese Patients with Moderate-to-Severe Chronic Obstructive Pulmonary Disease: The Chinese Cohort from the LANTERN Study.
Zhong N; Wang C; Zhou X; Zhang N; Humphries M; Wang L; Patalano F; Banerji D
COPD; 2016 Dec; 13(6):686-692. PubMed ID: 27715335
[TBL] [Abstract][Full Text] [Related]
38. Lung function, pharmacokinetics, and tolerability of inhaled indacaterol maleate and acetate in asthma patients.
Miller D; Vaidya S; Jauernig J; Ethell B; Wagner K; Radhakrishnan R; Tillmann HC
Respir Res; 2020 Sep; 21(1):248. PubMed ID: 32967685
[TBL] [Abstract][Full Text] [Related]
39. Cost-effectiveness of twice-daily indacaterol/glycopyrrolate inhalation powder for the treatment of moderate to severe COPD in the US.
Rajagopalan K; Bloudek L; Marvel J; Dembek C; Kavati A
Int J Chron Obstruct Pulmon Dis; 2018; 13():3867-3877. PubMed ID: 30568438
[TBL] [Abstract][Full Text] [Related]
40. Long-term safety of glycopyrrolate: A randomized study in patients with moderate-to-severe COPD (GEM3).
Mahler DA; Gifford AH; Satti A; Jessop N; Eckert JH; D'Andrea P; Mota F; Banerjee R
Respir Med; 2016 Jun; 115():39-45. PubMed ID: 27215502
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
